Molecular medicine: A path towards a personalized medicine;Medicina molecular: Um passo em direção à medicina personalizada

Revista Brasileira de Psiquiatria

Volumn 34, Issue 1, 2012, Pages 82-91

  de Miranda, Debora Marques ^a   Mamede, Marcelo ^a   de Souza, Bruno Rezende ^a   de Almeida Barros, Alexandre Guimarães ^a   Magno, Luiz Alexandre ^a   Alvim Soares, Antônio ^a   Rosa, Daniela Valadão ^a   de Castro, Célio José ^a   Malloy Diniz, Leandro ^a   Gomez, Marcus Vinícius ^a   de Marco, Luiz Armando ^a   Correa, Humberto ^a   Romano Silva, Marco Aurélio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CARBON 11; FIALURIDINE; IODINE 124; NITROGEN 13; OMEGA CONOTOXIN MVIIA; OXYGEN 15; PHONEUTRIA TOXIN; RACLOPRIDE C 11; RADIOISOTOPE; SPIDER VENOM; TRACER; TX3 3; TX3 4; TX3 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIORAL SCIENCE; BIPOLAR DISORDER; BRAIN; CAENORHABDITIS ELEGANS; CELL LEVEL; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DEVELOPMENTAL COORDINATION DISORDER; DOPAMINERGIC SYSTEM; DRUG COST; DRUG RESEARCH; DRUG TARGETING; GRAFT SURVIVAL; HEART ARRHYTHMIA; HUMAN; HUNTINGTON CHOREA; HYPERACTIVITY; IMAGING SYSTEM; LEARNING DISORDER; MENTAL DISEASE; MENTAL HEALTH; MENTAL HEALTH SERVICE; MICROPOSITRON EMISSION TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; MOLECULAR BIOLOGY; MOLECULAR IMAGING; MOLECULAR MEDICINE; MOOD DISORDER; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPSYCHOLOGY; NEUROTRANSMISSION; NON INVASIVE PROCEDURE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ONCOLOGY; PAIN; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; RAT; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; TREATMENT RESPONSE; WORM; ZEBRA FISH;

EID: 84858055781     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1516-4446(12)70015-6     Document Type: Article

References (67)

1. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet. 2007; 8(5):353-67.
2. Souza BR, Tropepe V. The role of dopaminergic signaling during larval zebrafish brain development: a tool for investigating the developmental basis of neuropsychiatric disorders. Rev Neurosci. 2011; 22(1):107-19.
3. Rinkwitz S, Mourrain P, Becker TS. Zebrafish: an integrative system for neurogenomics and neurosciences. Prog Neurobiol. 2011; 93(2):231-43.
4. Kabashi E, Champagne N, Brustein E, Drapeau P. In the swim of things: recent insights to neurogenetic disorders from zebrafish. Trends Genet. 2010; (8):373-81.
5. Luedtke S, O'Connor V, Holden-Dye L, Walker RJ. The regulation of feeding and metabolism in response to food deprivation in Caenorhabditis elegans. Invert Neurosci. 2010; 10(2):63-76.
6. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007; 12(10):934-45.
7. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008; 13:27-35.
8. th ed. University of Oregon Press, Eugene.2007.
9. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005; 10(1):79-104.
10. Panula P, Chen YC, Priyadarshini M, Kudo H, Semenova S, Sundvik M, Sallinen V. The comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human neuropsychiatric diseases. Neurobiol Dis. 2010; 40(1):46-57.
11. Albert KA, Hemmings HC Jr, Adamo AI, Potkin SG, Akbarian S, Sandman CA, Cotman CW, Bunney WE Jr, Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry. 2002; 59(8):705-12.
12. Ishikawa M, Mizukami K, Iwakiri M, Asada T. Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(6):1177-81.
13. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004; 36(2):131-7.
14. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci. 2007; 28(4):166-72.
15. Souza BR, Romano-Silva MA, Tropepe V. The role of dopamine in the early neurodevelopment and behaviour of zebrafish. J Neurosc. 2011; 31(14):5512-5525.
16. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol. 2009; 49:327-47.
17. Gonzalez-Burgos G, Hashimoto T, Lewis DA. Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep. 2010; 12(4):335-44.
18. Di Cristo G. Development of cortical GABAergic circuits and its implications for neurodevelopmental disorders. Clin Genet. 2007; 72(1):1-8.
19. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341(15):1097-105.
20. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303(3):235-41.
21. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol The.r 2010; 87(6):652-62.
22. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000; 404(6778):661-71.
23. Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol. 2008; 59:55-92.
24. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006; 443(7109):289-95.
25. Mullaney BC, Ashrafi K. C. elegans fat storage and metabolic regulation. Biochim Biophys Acta. 2009; 1791(16):474-8.
26. Watts JL. Fat synthesis and adiposity regulation in Caenorhabditis elegans. Trends Endocrinol Metab. 2009; 20(2):58-65.
27. Ashrafi K. The C. elegans Research Community. In: WormBook. 2007. p.1-20.
28. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature. 2003; 421(6920):268-72.
29. Greer ER, Perez CL, Van Gilst MR, Lee BH, Ashrafi K. Neural and molecular dissection of a C. elegans sensory circuit that regulates fat and feeding. Cell Metab. 2008; 8(2):118-31.
30. Cohen M, Reale V, Olofsson B, Knights A, Evans P, de Bono M. Coordinated regulation of foraging and metabolism in C. elegans by RFamide neuropeptide signaling. Cell Metab. 2009; 9(4):375-85.
31. Kok P, Roelfsema F, Frölich M, van Pelt J, Stokkel MP, Meinders AE, Pijl H. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006; 291(5):E1038-E1043.
32. Tseng YH, Cypess AM, Kahn CR.Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov. 2010; 9(6):465-82.
33. Campi-Azevedo AC, Boson W, De Marco L, Romano-Silva MA, Correa H. Association of the serotonin transporter promoter polymorphism with suicidal behavior. Mol Psychiatry. 2003; 8(11):899-900.
34. Neves FS, Silveira G, Romano-Silva MA, Malloy-Diniz L, Ferreira AA, De Marco L, Correa H. Is the 5-HTTLPR polymorphism associated with bipolar disorder or with suicidal behavior of bipolar disorder patients? Am J Med Genet B Neuropsychiatr Genet. 2008;147B(1):114-6.
35. Paula JJ, Schlottfeldt CG, Moreira L, Cotta M, Bicalho MA, Moraes EN, Romano-Silva MA, Corrêa H, Malloy-Diniz LF. Psychometric properties of a brief neuropsychological protocol for use in geriatric populations. Rev Psiquiatr Clín. 2010; 37:246-50.
36. Malloy-Diniz LF, Neves FS, Abrantes SS, Fuentes D, Corrêa H. Suicide behavior and neuropsychological assessment of type I bipolar patients? J Affect Disord. 2009; 112(1-3):231-6.
37. Moreira L, Neves FS, Schlottfeldt CG, Abrantes SSC, Moraes PHP, Romano-Silva MA, Corrêa H, Malloy-Diniz L. Visual and verbal memory in euthymic bipolar patients: Impacts of subtype, psychotic symptoms and suicide behavior. Clin Neuropsychiatry. 2010; 7(3):116-20.
38. da Rocha FF, Malloy-Diniz L, Lage NV, Romano-Silva MA, de Marco LA, Correa H. Decision-making impairment is related to serotonin transporter promoter polymorphism in a sample of patients with obsessive compulsive disorder. Behav Brain Res. 2008; 195(1):159-63.
39. Lage GM, Malloy-Diniz LF, Matos LO, Bastos MA, Abrantes SS, Corrêa H. Impulsivity and the 5-HTTLPR polymorphism in a non-clinical sample. Plos One. 2011; 6(2):e16927.
40. Rocha FF, Malloy-Diniz L, Lage NV, Corrêa H. Positive association between MET allele (BDNF Val66Met polymorphism) and obsessive- compulsive disorder. Rev Bras Psiquiatr. 2010; 32(3):323-4.
41. Moreira L, Neves FS, Romano-Silva MA, Malloy-Diniz LF, Corrêa H. BDNF and episodic memory in patients with bipolar disorder. Rev Bras Psiquiatr. 2011; 33(1):96-7.
42. Gomez MV, Kalapothakis E, Guatimosim C, Prado MA. Phoneutria nigriventer venom: a cocktail of toxins that affect ion channels. Cell Mol Neurobiol. 2002; 22(5-6):579-88.
43. Cordeiro MN, de Figueiredo SG, Valentim Ado C, Diniz CR, von Eickstedt VR, Gilroy J, Richardson M. Purification and amino acid sequences of six Tx3 type neurotoxins from the venom of the Brazilian 'armed' spider Phoneutria nigriventer (Keys). Toxicon. 1993; 31(1):35-42.
44. Souza AH, Ferreira J, Cordeiro Mdo N, Vieira LB, De Castro CJ, Trevisan G, Reis H, Souza IA, Richardson M, Prado MA, Prado VF, Gomez MV. Analgesic effect in rodents of native and recombinant Ph alpha 1beta toxin, a high-voltage-activated calcium channel blocker isolated from armed spider venom. Pain. 2008; 140(1):115-26.
45. Pinheiro AC, da Silva AJ, Prado MA, Cordeiro MD, Richardson M, Batista MC, de Castro Junior CJ, Massensini AR, Guatimosim C, Romano-Silva MA, Kushmerick C, Gomez MV. Phoneutria spider toxins block ischemia-induced glutamate release, neuronal death, and loss of neurotransmission in hippocampus. Hippocampus. 2009; 19(11):1123-9.
46. Agostini RM, do Nascimento Pinheiro AC, Binda NS, Romano Silva MA, do Nascimento Cordeiro M, Richardson M, Sena Guimarães AL, Gomez MV. Phoneutria spider toxins block ischemia-induced glutamate release and neuronal death of cell layers of the retina. Retina. 2011; Mar 9. (in press).
47. Xiong KL, Yang QW, Gong SG, Zhang WG. The role of postiron emission tomography imaging of beta-amyloid in patients with Alzheimer's disease. Nucl Med Comm. 2010; 31(1):4-11.
48. Murphy PS, McCarthy TJ, Dzik-Jurasz AS. The role of clinical imaging in oncological drug development. Br J Radiol. 2008; 81(969):685-92.
49. Schmidt KC, Turkheimer FE. Kinetic modeling in positron emission tomography. Q J Nucl Med. 2002; 46(1):70-85.
50. Cherry SR, Shao Y, Silverman RW, Meadors K, Siegel S, Chatziioannou A, Young JW, Jones WF, Moyers JC, Newport D, Boutefnouchet A, Farquhar TH, Andreaco M, Paulus MJ, Binkley DM, Nutt R, Phelps ME. MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci. 1997; 44(3):1161-6.
51. Fricker RA, Torres EM, Hume SP, Myers R, Opacka-Juffry J, Ashworth S, Brooks DJ, Dunnett SB. The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain: II Correlation between positron emission tomography and reaching behaviours. Neuroscience. 1997; 79(3):711-21.
52. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M, Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Zweit J, Humm J, Larson SM, Finn R, Blasberg R. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998; 58(19):4333-41.
53. Gambhir SS, Barrio JR, Phelps ME, Iyer M, Namavari M, Satyamurthy N, Wu L, Green LA, Bauer E, MacLaren DC, Nguyen K, Berk AJ, Cherry SR, Herschman HR. Imaging adenoviral- directed reporter gene expression in living animals with positron emission tomography. Proc Nat Acad Sci USA. 1999; 96(5):2333-8.
54. Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007; 30(4):377-88.
55. Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO. Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study. Neurology. 2011; 76(12):1085-90.
56. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A, Heukamp L, Buettner R, Ko YD, Ullrich RT, Smit E, Boellaard R, Lammertsma AA, Hallek M, Jacobs AH, Schlesinger A, Schulte K, Querings S, Stoelben E, Neumaier B, Thomas RK, Dietlein M, Wolf J. Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography. J Clin Oncol. 2011; 29(13):1701-8.
57. Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci. 2006; 27(6):310-6.
58. Pomper MG, Lee JS. Small Animal Imaging in Drug Development. Curr Pharm Des. 2005; 11(25):3247-72.
59. Nanni C, Torigian DA. Applications of Small Animal Imaging with PET, PET/CT, and PET/MR Imaging. PET Clin. 2009; 3(3): 243-50.
60. Brooks, DJ. Positron Emission Tomography and Single-Photon Emission Computed Tomography in Central Nervous System Drug Development. NeuroRx. 2005; 2(2):226-36.
61. Eckelman WC. The use of PET and knockout mice in the drug discovery process. Drug Discov Today. 2003; 8(9):404-10.
62. Cherry SR and Gambhir SS. Use of positron emission tomography in animal research. ILAR J. 2001; 42 (3): 219-232.
63. Cherry SR. Fundamentals of positron tomography and applications in preclinical drug development. J Clin Pharmacol. 2001 41: 482-91.
64. Lammerstma AA. Role of human and animal PET studies in drug development. International Congress Series 2004, 1265:3-11.
65. Aboagye EO, Price PM, Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today. 2001; 6(6):293-302.
66. Klimas MT. Positron Emission Tomography and Drug Discovery: Contributions to the Understanding of Pharmacokinetics, Mechanism of Action and Disease State Characterization. Mol Imaging Bio. 2002; 4(5):311-37.
67. Lancelot S, Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends in Pharmacol Sci. 2010; 31(9):411-7.